Shattuck Labs, Inc. (STTK)

Market Cap	37.09M
Revenue (ttm)	4.61M
Net Income (ttm)	-70.61M
Shares Out	47.90M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232,579
Open	0.8042
Previous Close	0.8240
Day's Range	0.7501 - 0.8468
52-Week Range	0.6922 - 4.9900
Beta	1.64
Analysts	Hold
Price Target	3.00 (+287.45%)
Earnings Date	Jul 31, 2025

About STTK

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involv...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: STTK
• Website: https://www.shattucklabs.com

Financial Performance

In 2024, Shattuck Labs's revenue was $5.72 million, an increase of 245.26% compared to the previous year's $1.66 million. Losses were -$75.41 million, -13.62% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for STTK stock is "Hold." The 12-month stock price target is $3.0, which is an increase of 287.45% from the latest price.

Price Target

$3.0

(287.45% upside)

Analyst Consensus: Hold